In diagnostics, CRISPR‐based platforms like SPEAR offer highly sensitive and rapid detection of critical cancer‐related mutations, such as KRAS, from liquid biopsies, enabling earlier diagnosis and disease monitoring [255]. The gene discussed is KRAS; the disease is cancer.